SCHEMBL19483312

SCHEMBL19483312

CNCCCCC(NC(C)(C)C)C(=O)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ KISS1R Q969F8 1/20 0.39
▸ CPB2 Q96IY4 1/20 0.33
▸ EPHX1 P07099 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19483326 1.00 KISS1R (0.39) KISS1RCPB2EPHX1
SCHEMBL24235774 0.87 KISS1R (0.40) KISS1RCPB2EPHX1
SCHEMBL18177134 0.86 POLB (0.35) —
SCHEMBL13166779 0.86 POLB (0.35) —
SCHEMBL26743884 0.84 CPB2 (0.40) KISS1RCPB2
SCHEMBL19483310 0.83 ITGB3 (0.34) —
SCHEMBL27424230 0.83 POLB (0.41) EPHX1
SCHEMBL19483324 0.83 KDM4E (0.48) EPHX1
SCHEMBL19483322 0.83 KDM4E (0.48) EPHX1
SCHEMBL19483313 0.83 ITGB3 (0.34) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10626144-B2 Peptide derivatives and uses thereof NOSOPHARM (FR) 2020-04-21 — — US disclosed
US-20170298097-A1 Peptide Derivatives and Uses Thereof NOSOPHARM (FR) 2017-10-19 — — US disclosed
US-20170298097-A1 Peptide Derivatives and Uses Thereof NOSOPHARM (FR) 2017-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626144-B2 Peptide derivatives and uses thereof VIP, IAPP, NGLY1 KISS1R 381/4885CPB2 236/4885EPHX1 4301/4885
US-20170298097-A1 Peptide Derivatives and Uses Thereof VIP, IAPP, NGLY1 KISS1R 381/4885CPB2 236/4885EPHX1 4301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback